This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Interview: Q BioMed accelerates advances in vascular therapeutics
Feb 24, 2016Tags:BiotechBusiness developmentPharma
Ensuring that all the necessary resources are in place to build a sustainable business is a key challenge for most entrepreneurs. They need access to capital and expertise without having to give it away cheaply. Q BioMed Inc CEO Denis Corin explains to Mike Ward, global director of content for Informa’s pharma insight products, how his biomedical acceleration and development company is providing target companies and assets access to strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential.
The company is agnostic in terms of geography, therapeutic focus, or development phase. One of Q BioMed’s recent acquisitions was Mannin Research Inc., a biotech that is developing a new class of vascular therapeutics and led Dr. Susan E. Quaggin, chief of the division of nephrology and director of the Feinberg Cardiovascular Research Institute at Northwestern University in Chicago. The primary target indication is for a first-in-class therapeutic eyedrop for the treatment of glaucoma in adults and children.
Interviewee: Denis Corin – CEO, Q BioMed Inc.
Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Link to article: http://bit.ly/1oHrviU
Share this article:
Newsletter sign up
An online journal for executives in the life sciences, partneringNEWS™ is focused on the people behind the deals. Putting a human face to a collaboration agreement gives business development professionals the ability to get behind the headlines.
Sign up today to the free newsletter and never miss any new content.